

## Rani Therapeutics Holdings, Inc. (RANI: NASDAQ)

### RANI: Second Quarter Financial Results

Rani's valuation relies on a DCF model and a 15% discount rate applied to our cash flow estimates. We apply a success probability of 30% to RT-102, 30% to RT-111 and 25% to RT-105. The model includes contributions from the United States and rest of world.

Current Price (8/11/2025) **\$0.50**  
**Valuation \$8.00**

### SUMMARY DATA

52-Week High **3.75**  
 52-Week Low **0.39**  
 One-Year Return (%) **-77.9**  
 Beta **0.0**  
 Average Daily Volume (sh) **1,934,888**

Shares Outstanding (mil) **73.0**  
 Market Capitalization (\$mil) **36.5**  
 Short Interest Ratio (days) **1.8**  
 Institutional Ownership (%) **11.2**  
 Insider Ownership (%) **21.5**

Annual Cash Dividend **\$0.00**  
 Dividend Yield (%) **0.00**

5-Yr. Historical Growth Rates  
 Sales (%) **N/A**  
 Earnings Per Share (%) **N/A**  
 Dividend (%) **N/A**

P/E using TTM EPS **N/A**  
 P/E using 2025 Estimate **N/A**  
 P/E using 2026 Estimate **N/A**

Zacks Rank **N/A**

### OUTLOOK

Rani is a clinical-stage biotherapeutics company developing the ingestible robotic RaniPill (RP) that enables oral delivery of biologics & other large molecules. Its pipeline features clinical assets RT-102 (teriparatide for osteoporosis) & RT-111 (ustekinumab for psoriasis). Both programs have completed Ph1 trials characterizing safety tolerability & pharmaco-kinetics. Adalimumab for psoriasis (RT-105) & teriparatide for hypo-parathyroidism (RT-110) are in preclinical development. A deal for RT-114 was recently signed with ProGen for development of GLP-1/2 for obesity & diabetes.

Other Rani initiatives include development of larger capacity pills & collaborations with biopharmaceutical companies. Other efforts include the start of a Phase II for RT-102 and a combined dose finding/Phase II for RT-111.

RP expands delivery options for biologics that now require parenteral administration. An oral option would provide product life cycle management, improved comfort of administration, greater compliance and improved dosing regimens which would improve efficacy and reduce side effects.

We expect clinical trials will be completed and approval granted for RT-102 and RT-111 in 2027. If RP proves successful in delivering biologics for these initial indications, we see material penetration opportunity into the \$300B+ biologics market which offers few oral alternatives.

**Risk Level** Above Average  
**Type of Stock** Small-Growth  
**Industry** Med-Biomed/Gene

### ZACKS ESTIMATES

#### Revenue

(In millions of USD)

	Q1	Q2	Q3	Q4	Year
	(Mar)	(Jun)	(Sep)	(Dec)	(Dec)
2024	\$0.0 A	\$0.0 A	\$0.0 A	\$1.0 A	\$1.0 A
2025	\$0.1 A	\$0.0 A	\$0.0 E	\$0.0 E	\$0.1 E
2026					\$0.0 E
2027					\$0.0 E

#### Earnings per Share

	Q1	Q2	Q3	Q4	Year
2024	-\$0.29 A	-\$0.26 A	-\$0.24 A	-\$0.27 A	-\$1.05 A
2025	-\$0.22 A	-\$0.18 A	-\$0.09 E	-\$0.09 E	-\$0.49 E
2026					-\$0.36 E
2027					-\$0.37 E

## WHAT'S NEW

On August 7<sup>th</sup>, Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) reported second quarter 2025 results. Since our last update, Rani has signed a research agreement with Chugai Pharmaceutical, presented ProGen's PG102 pre-clinical data at ENDO and raised additional capital in preparation for a 2H:25 launch of the Phase I RT-114 trial. Rani continues to interact with prospects to sign a deal with an established biopharmaceutical company which may include upfronts, milestones and royalties.

### **2Q:25 Operational and Financial Results**

Rani reported second quarter results in a [press release](#) and [Form 10-Q](#) filing with the SEC on August 7<sup>th</sup>. For the quarter ending June 30<sup>th</sup>, 2025, no revenues were recognized and operating expense was (\$10.5) million and net loss per share for Class A shareholders was (\$0.18).

- Research and development expenses totaled \$5.5 million, down 10% from \$6.1 million mostly due to lower compensation costs, a smaller team partially offset by slightly higher third-party service costs;
- General & administrative expenses were \$5.0 million, falling 22% from \$6.4 million on lower compensation costs, reduction in workforce and a fall in third party services;
- Net interest expense was (\$719,000) vs. (\$837,000) due to lower cash balances;
- Non-controlling interest was (\$4.5) million vs. (\$6.6) million;
- Net loss for Class A shareholders was (\$6.7) million vs. (\$6.8) million or (\$0.18) and (\$0.26) per share.

As of June 30<sup>th</sup>, 2025, cash and marketable securities totaled \$10.2 million. This amount compares to the \$27.6 million balance held at the end of 2024. Long-term debt was held on the balance sheet at \$17.2 million. Cash used in operations and for capital expenditures for the first half of 2025 was (\$14.0) million versus (\$18.5) million in the same prior year period. During the second quarter, Rani repaid \$3.8 million in debt bringing the total to \$7.5 million for 2025. Offsetting this outflow was \$3.9 million from the exercise of warrants. Following the end of the second quarter, Rani raised an additional \$3.0 million from the issuance of 7.5 million shares at \$0.40 per share.

### **Research Agreement with Chugai**

A May 19<sup>th</sup> [press release](#) informed investors that Rani had signed a research agreement with Chugai Pharmaceutical Co. on August 13<sup>th</sup>, 2024. The agreement granted Chugai rights to develop two molecules with undisclosed targets. Since the signing, the partner has demonstrated bioavailability comparable with delivery via the subcutaneous route for both molecules. The partners are now evaluating feasibility of applying Rani's technology to these antibodies.

Chugai Pharmaceutical is a research and development-oriented pharmaceutical company based in Tokyo, Japan established in 1925. It operates as a subsidiary of Hoffmann-La Roche which owns a 62% stake and trades on multiple exchanges including the OTC under the ticker CHGKY. Chugai has developed and marketed several globally recognized pharmaceuticals, often in partnership with Roche. This includes Hemlibra, Actemra, and Alecensa among other products. Chugai also discovered orforglipron and licensed it to Eli Lilly in 2018.

### **Endocrine Society's Annual Meeting (ENDO 2025) Poster**

Rani participated in the 2025 Endocrine Society Annual Meeting, which was held in San Francisco July 12<sup>th</sup> to 15<sup>th</sup>. As described in a July 14<sup>th</sup> [press release](#), company scientist Anvesh Dasari, Ph.D. presented a poster entitled Oral Delivery of a Bispecific GLP-1/GLP-2 Receptor Agonist (PG-102) via a Robotic Pill (RT-114) Achieves Bioequivalence to Subcutaneous Injection in Canines. The work presented preclinical data including delivery success rate, oral bioavailability for RP vs. subcutaneous (SC) delivery and weight loss in the canine models. 12.0 milligrams of PG-102, a GLP-1/GLP-2 receptor agonist was delivered into a population of 16 healthy canines. Six were administered PG-102 by SC injection and oral administration of the RP was given to 10 canines. Pharmacokinetic and pharmacodynamic data was measured such as serum drug concentrations, food intake and body weight, safety, tolerability and delivery reliability.

The Rani Pill was successfully delivered in nine of ten subjects and generated oral bioavailability of 111% relative to subcutaneous delivery. Food consumption was inversely correlated to serum drug concentrations for RT-114 and weight loss was comparable between the two arms of the study. Graphic details of the findings are included below.

## Exhibit I – Data from Preclinical Evaluation of PG-102 and RT-114

Fig 1. RP Success Rate




Fig 2. PK of Oral vs SC PG-102 in Dogs




Fig 3. PK/PD Relationship for RT-114





Fig. 4. Average Peak Weight Loss



Source: Rani Therapeutics Poster entitled Oral Delivery of a Bispecific GLP-1/GLP-2 Receptor Agonist (PG-102) via a Robotic Pill (RT-114) Achieves Bio-equivalence to Subcutaneous Injection in Canines

### RT-114 AND PG-102 Results

#### ProGen Collaboration Details

In June 2024, Rani [announced](#) a collaboration with [ProGen Co., Ltd.](#) to develop an oral obesity treatment combining ProGen's FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with Rani's Rani Pill HC. Rani entered into a definitive agreement with ProGen to develop a new product designated RT-114, an oral dose of ProGen's PG-102. The companies will equally share the costs of development of RT-114 and divide geographies between them. Details of the arrangement between the two companies can be found in the second quarter 2024 [Form 10-Q](#).<sup>1</sup>

Following the deal between Rani and ProGen, the partners have begun a development plan for the GLP-1/GLP-2 dual agonist. As of August 2025, ProGen has completed its Phase I trial for PG-102 with the primary endpoints of safety and tolerability and has started a Phase II study with further details on timing and readout expected later this year. Rani is advancing a head-to-head preclinical comparison of orally administered PG-102 using the RaniPill capsule (RT-114) to 16 healthy canines. Data from this study was presented at the ENDO meeting with details included above.

#### ProGen Clinical Trials

ProGen's [Phase I](#) trial underway for PG-102 announced preliminary results for the repeat-dose portion (Phase Ic) of its Phase I study. The candidate produced an average weight loss in subjects (N=73) of 4.8% after five weeks of dosing. Subcutaneous PG-102 was well tolerated with subjects able to titrate to the target dose in one month. There were no treatment discontinuations. Additional data was presented at the [Asian Association for the Study of Diabetes](#) (AASD) which was held March 28<sup>th</sup> to 30<sup>th</sup>. Rani's Senior Strategic Advisor, Jesper Høiland hypothesizes that the rapid titration may facilitate faster onset, shortening the time between initial administration and target weight loss. It is notable that the 4.8% average weight loss was achieved after five weeks compared to the four to five months required by approved GLP-1 agonists.<sup>2</sup> ProGen is planning a [Phase II](#) study of PG-102 that will compare the candidate with placebo in obesity and Type 2 diabetes. Six sites in Korea have been identified and sites outside Korea are also being added.

#### Rani Preclinical Trials

Rani is running its preclinical study, delivering either a 12 mg dose of PG-102 using RaniPill (N=10) or subcutaneously (N=6). This is estimated to be equivalent to a 60 mg dose in humans. The study is evaluating endpoints including safety, tolerability and reliability of the RaniPill capsule as well as pharmacokinetics, which is serum concentration measured by enzyme-linked immunosorbent assay (ELISA). Body weight and food intake are also being measured.

<sup>1</sup> See .pdf page 38 which is the beginning of the Collaboration Agreement listed as Exhibit 10.1

<sup>2</sup> Ryan, D.H., et al. [Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial](#). Nature Medicine. May 2024. See Figure 1.

## Milestones

- Preclinical data [readout](#) for RT-116 – February 2025
- Research [agreement](#) with Chugai Pharmaceutical – May 2025
- Launch of Phase I trial for RT-114 – 2H:25
- End of NASDAQ minimum market value requirement resolution period – October 2025
- End of NASDAQ \$1.00 minimum bid price resolution period – December 2025

### Exhibit II – Rani Therapeutic Pipeline

	INDICATION(S)	DISCOVERY	PRE-CLINICAL	PHASE 1	PHASE 2	PARTNER	NEXT EXPECTED KEY MILESTONE*
<b>OBESITY PROGRAMS</b>							
RT-114	Obesity	GLP-1/GLP-2**					Initiate Phase 1 in mid-2025
RT-116	Obesity	Semaglutide					Continue Preclinical Discovery Work
<b>IMMUNOLOGY PROGRAMS</b>							
RT-105	Rheumatoid Arthritis	Adalimumab***					Initiate Phase 1
RT-111	Psoriasis	Ustekinumab***					Advance Clinical Development at Higher Doses
<b>ENDOCRINOLOGY PROGRAMS</b>							
RT-102	Osteoporosis	PTH-OP					Initiate Phase 2
RT-110	Hypo-parathyroidism	PTH-Hypo					Initiate Phase 1

Source: Rani Therapeutics [2024 Results Slide Deck, March 2025](#)

## Valuation

We update our valuation estimate to reflect an updated share count and near term capital raises. Applying the DCF model to our cash flow estimates yields a target price of \$8.00.

## Summary

Rani reports second quarter results as it seeks sufficient capital to start its RT-114 trial. The capital raising environment has been very tight; however, Rani's technology has demonstrated effective delivery of biologics with high bioavailability. This is an attractive feature for many established biopharmaceutical companies seeking to improve drug delivery. Rani management is in discussions with multiple partners which may generate a licensing deal and upfront capital. We update our valuation to \$8.00 per share to reflect the updated share count.

## PROJECTED FINANCIALS


### Rani Therapeutics Holdings, Inc. - Income Statement

RANI Therapeutics, Inc.	2024 A	Q1 A	Q2 A	Q3 E	Q4 E	2025 E	2026 E	2027 E
<b>Revenues</b>	<b>\$1,028</b>	<b>\$172</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$172</b>	<b>\$0</b>	<b>\$0</b>
Research & Development	\$26,682	\$6,570	\$5,505	\$5,360	\$6,225	\$23,660	\$24,606	\$25,000
General & Administrative	\$23,946	\$5,615	\$5,000	\$5,100	\$5,100	\$20,815	\$21,439	\$23,000
Other Items	\$3,714	\$0	\$0	\$0	\$0	\$0	\$0	\$0
<b>Operating Income</b>	<b>(\$53,314)</b>	<b>(\$12,013)</b>	<b>(\$10,505)</b>	<b>(\$10,460)</b>	<b>(\$11,325)</b>	<b>(\$44,303)</b>	<b>(\$46,046)</b>	<b>(\$48,000)</b>
<i>Operating Margin</i>								
Interest Income, net	\$1,763	\$218	\$158	\$650	\$550	\$1,000	\$950	\$1,000
Other Income (Loss)	(\$5,033)	(\$943)	(\$877)	(\$920)	(\$920)	(\$3,660)	(\$3,600)	(\$3,600)
<b>Loss Before Income Taxes</b>	<b>(\$56,584)</b>	<b>(\$12,738)</b>	<b>(\$11,224)</b>	<b>(\$10,730)</b>	<b>(\$11,695)</b>	<b>(\$46,963)</b>	<b>(\$48,696)</b>	<b>(\$50,600)</b>
Income Tax	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
Non-Controlling Interest	(\$26,566)	(\$5,474)	(\$4,532)	(\$5,258)	(\$5,731)	(\$23,012)	(\$23,861)	(\$24,794)
<b>Net Loss</b>	<b>(\$30,018)</b>	<b>(\$7,264)</b>	<b>(\$6,692)</b>	<b>(\$5,472)</b>	<b>(\$5,964)</b>	<b>(\$23,951)</b>	<b>(\$24,835)</b>	<b>(\$25,806)</b>
<b>Net Loss Per Share</b>	<b>(\$1.05)</b>	<b>(\$0.22)</b>	<b>(\$0.18)</b>	<b>(\$0.09)</b>	<b>(\$0.09)</b>	<b>(\$0.49)</b>	<b>(\$0.36)</b>	<b>(\$0.37)</b>
Weighted Average Shares	28,476	33,440	36,542	58,000	68,000	48,996	68,500	69,000

Source: Company Filing // Zacks Investment Research, Inc. Estimates

## HISTORICAL STOCK PRICE

Rani Therapeutics Holdings, Inc. – Share Price Chart<sup>3</sup>



<sup>3</sup> Source: Zacks Research System

---

## DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

### ANALYST DISCLOSURES

I, John Vandermosten, hereby certify that the views expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

### INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.

Zacks SCR has received compensation from the issuer directly or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted.

### POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business. SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover. SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

### ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

### CANADIAN DISCLAIMER

This research report is a product of Zacks SCR and prepared by a research analyst who is employed by or is a consultant to Zacks SCR. The research analyst preparing the research report is resident outside of Canada and is not an associated person of any Canadian registered adviser and/or dealer and, therefore, the analyst is not subject to supervision by a Canadian registered adviser and/or dealer, and is not required to satisfy the regulatory licensing requirements of any Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and is not required to otherwise comply with Canadian rules or regulations.